Alexander Burik, Author at Labiotech.eu

About

Born in Chicago, I grew up close to Frankfurt, Germany. I hold an MSc in Neuroscience from University College London and a BA in Biochemistry from Knox College in the US.
Outside of science-related activities, I enjoy skiing and writing music.

Articles by Alexander Burik

News and Trends 3 May 2018

World’s First Gene Therapy Developer Raises $128M for Hemophilia and Huntington’s

uniQure has raised a substantial public offering on the NASDAQ. The funding could help the Dutch biotech advance two new gene therapies after the withdrawal of its first treatment. Amsterdam-based uniQure has raised an ambitious $128M (€107M) in a public offering at the beginning of next week. The Dutch biotech develops gene therapies for hemophilia and Huntington’s disease, for […]

May 3, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 30 Apr 2018

Record Series B Financing Supports Antibody Cancer Therapy

Crescendo Biologics has raised €57M in in the largest disclosed Series B financing in the European biotech sector this year. The company will use the funds to develop its antibody cancer treatment that activates white blood cells to fight tumors. Crescendo Biologics, based in Cambridge, UK, has raised €57M in the largest disclosed Series B financing for the European […]

April 30, 2018 - 2 minutesmins - By Alexander Burik

Startup Scout 27 Apr 2018

This Portuguese Biotech is Developing a Faster Antimicrobial Susceptibility Test

Today, we’re in Matosinhos, Portugal, visiting FASTinov, a biotech that is developing an antimicrobial susceptibility test that are faster than standard assays. The technology could help battle antibiotic resistance by identifying appropriate treatments. Mission: Founded in 2013, FASTinov is developing a new type of test for antimicrobial susceptibility that can help combat the global health problem of antibiotic […]

April 27, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 26 Apr 2018

Israeli Cell Therapy for Muscle Injury Will Start Phase III Trial in US

Pluristem Therapeutics will start a Phase III trial this year in the US for its pioneering cell therapy that uses placenta cells to restore muscle injuries. Pluristem Therapeutics, an Israeli biotech and world-leader in cell therapies, has received a green light from the FDA to start a Phase III study in the US. The trial will test […]

April 26, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 25 Apr 2018

Cancer Treatment Targeting DNA Repair is Tested in Humans for the First Time

Onxeo has initiated a Phase I trial testing its first-in-class cancer treatment that works by inhibiting the repair of tumor DNA. Onxeo, a French biotech, has dosed its first patient in a Phase I study testing its cancer treatment AsiDNA, the first treatment of its kind, for advanced solid tumors. The news follows the Phase […]

April 25, 2018 - 1 minutemin - By Alexander Burik

News and Trends 24 Apr 2018

Fundraising Boosts Italian Red Blood Cell Therapy

EryDel has raised €26.5M to develop a red blood cell drug delivery system to treat a rare disease of the immune and nervous systems. Italian biotech EryDel has raised €26.5M to complete a Phase III trial testing a unique technology to treat ataxia telangiectasia, a rare genetic disorder. The fundraising was led by Sofinnova Partners, a leading European venture […]

April 24, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 24 Apr 2018

New Class of Antibiotics Combats the Three Deadliest Bacteria in the World

A new class of antibiotics developed by Polyphor has been shown to be effective against the three most dangerous drug-resistant bacteria in the world. Polyphor’s novel class of antibiotics has been shown to effectively combat the three bacteria marked as critical, priority 1 by the World Health Organization. To date, there are very limited to no […]

April 24, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 20 Apr 2018

Gene Therapy For Beta-Thalassemia Could Eliminate Need for Transfusions

Bluebird bio has obtained results from two clinical studies showing its new gene therapy could eliminate the need for red blood cell transfusions in patients with beta-thalassemia. The company plans to file for an EU approval of its treatment later this year. US firm bluebird bio has results from two clinical studies showing its LentiGlobin gene […]

April 20, 2018 - 2 minutesmins - By Alexander Burik

BenevolentAI Artificial Intelligence Fundraising

News and Trends 19 Apr 2018

Major $115M Fundraising Fuels AI Drug Development

BenevolentAI has raised a massive second round of fundraising to expand the drug developing capabilities of its artificial intelligence technology. The technology could significantly increase the speed and efficiency of the drug discovery process. BenevelontAI, based in London, has raised an impressive $115M (€93M) to advance its use of AI in drug development. The funding, raised from […]

April 19, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 18 Apr 2018

Finnish Rapid Molecular Diagnostic Test Enters European Market

Mobidiag, a Finnish biotech, has launched a diagnostic test that can rapidly detect the most common disease-causing microbes in the gut. The test can help manage infections more effectively at an earlier stage. Mobidiag has launched a molecular diagnostic test on the European market that checks patient samples for numerous bacterial targets, including the most […]

April 18, 2018 - 1 minutemin - By Alexander Burik

Interview 18 Apr 2018

What Lies Ahead for European Cell and Gene Therapies?

Cell and gene therapies have recently made big advances in providing effective treatments for a variety of conditions, from cancers to rare diseases. Nonetheless, there are still significant challenges ahead before the technologies can become a viable treatment option for most patients. What if you could treat a disease on the level of tissue and […]

April 18, 2018 - 5 minutesmins - By Alexander Burik

More News! 16 Apr 2018

Epitopes Come to the Rescue for One of the Most Common Autoimmune Diseases

The British-Belgian biotech Apitope has obtained positive Phase I results for its first-in-class treatment for Graves’ disease, one of the most common autoimmune diseases. Apitope has obtained positive clinical results indicating its treatment for Graves’ disease is safe and well-tolerated. A common autoimmune disease affecting the thyroid, Graves’ disease occurs when a patient’s immune system […]

April 16, 2018 - 2 minutesmins - By Alexander Burik

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Alexander Burik

About

Articles by Alexander Burik

World’s First Gene Therapy Developer Raises $128M for Hemophilia and Huntington’s

Record Series B Financing Supports Antibody Cancer Therapy

This Portuguese Biotech is Developing a Faster Antimicrobial Susceptibility Test

Israeli Cell Therapy for Muscle Injury Will Start Phase III Trial in US

Cancer Treatment Targeting DNA Repair is Tested in Humans for the First Time

Fundraising Boosts Italian Red Blood Cell Therapy

New Class of Antibiotics Combats the Three Deadliest Bacteria in the World

Gene Therapy For Beta-Thalassemia Could Eliminate Need for Transfusions

Major $115M Fundraising Fuels AI Drug Development

Finnish Rapid Molecular Diagnostic Test Enters European Market

What Lies Ahead for European Cell and Gene Therapies?

Epitopes Come to the Rescue for One of the Most Common Autoimmune Diseases

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Alexander Burik

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!